KR100383389B1 - Process for Preparing Healthful Salt Containing Mineral Gluconate - Google Patents
Process for Preparing Healthful Salt Containing Mineral Gluconate Download PDFInfo
- Publication number
- KR100383389B1 KR100383389B1 KR10-2000-0087338A KR20000087338A KR100383389B1 KR 100383389 B1 KR100383389 B1 KR 100383389B1 KR 20000087338 A KR20000087338 A KR 20000087338A KR 100383389 B1 KR100383389 B1 KR 100383389B1
- Authority
- KR
- South Korea
- Prior art keywords
- salt
- gluconate
- functional
- salt containing
- mineral
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 67
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 11
- 229910052500 inorganic mineral Inorganic materials 0.000 title abstract description 18
- 239000011707 mineral Substances 0.000 title abstract description 18
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 title abstract description 14
- 229940050410 gluconate Drugs 0.000 title abstract description 11
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 18
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims abstract description 12
- AEQDJSLRWYMAQI-UHFFFAOYSA-N 2,3,9,10-tetramethoxy-6,8,13,13a-tetrahydro-5H-isoquinolino[2,1-b]isoquinoline Chemical compound C1CN2CC(C(=C(OC)C=C3)OC)=C3CC2C2=C1C=C(OC)C(OC)=C2 AEQDJSLRWYMAQI-UHFFFAOYSA-N 0.000 claims abstract description 8
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims abstract description 8
- 239000001110 calcium chloride Substances 0.000 claims abstract description 8
- 229910001628 calcium chloride Inorganic materials 0.000 claims abstract description 8
- 239000013078 crystal Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 8
- 235000012207 sodium gluconate Nutrition 0.000 claims abstract description 8
- 239000000176 sodium gluconate Substances 0.000 claims abstract description 8
- 229940005574 sodium gluconate Drugs 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 8
- 229910001629 magnesium chloride Inorganic materials 0.000 claims abstract description 6
- 238000001953 recrystallisation Methods 0.000 claims abstract description 6
- 238000001816 cooling Methods 0.000 claims abstract description 5
- 238000001035 drying Methods 0.000 claims abstract description 5
- 238000011043 electrofiltration Methods 0.000 claims abstract description 3
- 238000010438 heat treatment Methods 0.000 claims abstract description 3
- 239000007788 liquid Substances 0.000 claims abstract description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 5
- 229960001763 zinc sulfate Drugs 0.000 claims description 5
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 3
- 235000010755 mineral Nutrition 0.000 abstract description 17
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 abstract description 14
- 206010020772 Hypertension Diseases 0.000 abstract description 10
- 235000011148 calcium chloride Nutrition 0.000 abstract description 7
- 235000011164 potassium chloride Nutrition 0.000 abstract description 7
- 239000001103 potassium chloride Substances 0.000 abstract description 7
- 241000186000 Bifidobacterium Species 0.000 abstract description 5
- 241000894006 Bacteria Species 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 4
- 229940099596 manganese sulfate Drugs 0.000 abstract description 4
- 239000011702 manganese sulphate Substances 0.000 abstract description 4
- 235000007079 manganese sulphate Nutrition 0.000 abstract description 4
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 abstract description 4
- 230000035755 proliferation Effects 0.000 abstract description 4
- 210000000936 intestine Anatomy 0.000 abstract description 3
- 208000019553 vascular disease Diseases 0.000 abstract description 3
- 235000002639 sodium chloride Nutrition 0.000 description 66
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000018044 dehydration Effects 0.000 description 4
- 238000006297 dehydration reaction Methods 0.000 description 4
- 235000011147 magnesium chloride Nutrition 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 239000011572 manganese Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 210000000813 small intestine Anatomy 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- -1 sun salt Chemical class 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- HCHKCACWOHOZIP-IGMARMGPSA-N Zinc-65 Chemical compound [65Zn] HCHKCACWOHOZIP-IGMARMGPSA-N 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229960002713 calcium chloride Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229960002337 magnesium chloride Drugs 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960002816 potassium chloride Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/40—Table salts; Dietetic salt substitutes
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/04—Gluconic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/10—Drying, dehydrating
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/24—Heat, thermal treatment
Landscapes
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
각종 유용 미네랄을 글루콘산염의 형태로 함유하는 기능성 소금의 제조방법 및 전기 방법으로 제조된 기능성 소금을 제공한다. 본 발명의 미네랄-글루콘산염을 함유하는 기능성 소금의 제조방법은, 50 내지 90%(w/w)의 원료소금, 5 내지 25%(w/w)의 글루콘산 나트륨, 2 내지 12.5%(w/w)의 염화칼륨, 2 내지 12.5%(w/w)의 염화칼슘, 0.1 내지 2%(w/w)의 염화 마그네슘, 0.1 내지 2%(w/w)의 황산 아연 및 0.1 내지 1%(w/w)의 황산망간으로 구성된 원료물을 20 내지 30%(w/v)의 농도로 60 내지 80℃의 온도범위에서 가열하며 물에 용해시키는 공정; 전기 용액에 0.02 내지 0.05%(w/v)의 활성탄을 가하고 교반한 후, 여과하는 공정; 전기 여과액을 600 내지 700mmHg 감압조건하에서 가열농축하여 재결정핵을 생성한 후, 냉각시키고 재결정시키는 공정; 및, 결정을 탈수시키고, 수분함량이 0.5%(w/w) 이하가 되도록 건조하는 공정을 포함한다. 본 발명의 미네랄-글루콘산염을 함유하는 기능성 소금은 인체에 유용한 미네랄 성분들을 글루콘산염의 형태로 함유하고 있으므로, 체내에 섭취되었을 때, 장내 유익균인 비피더스균의 증식을 활성화시켜서 향상된 정장효과를 나타내며, 고혈압 등의 혈관계 질환의 발병율을 낮출 수 있을 것이다.The present invention provides a method for producing a functional salt containing various useful minerals in the form of gluconate salt and a functional salt prepared by an electric method. The method for producing a functional salt containing mineral-gluconate according to the present invention comprises the steps of: 50 to 90% (w / w) of raw salt, 5 to 25% (w / w) of sodium gluconate, 2 to 12.5% (w / w) of potassium chloride, 2 to 12.5% (w / w) of calcium chloride, 0.1 to 2% (w / w) of magnesium chloride, 0.1 to 2% w / w) of manganese sulfate at a concentration of 20 to 30% (w / v) in a temperature range of 60 to 80 캜 and dissolving in water; 0.02 to 0.05% (w / v) of activated carbon is added to the electric solution, stirred and filtered; Heating and concentrating the electrofiltration liquid under a reduced pressure of 600 to 700 mmHg to produce recrystallized nuclei, followed by cooling and recrystallization; And a step of dehydrating the crystals and drying so that the moisture content is 0.5% (w / w) or less. Since the functional salt containing the mineral-gluconate of the present invention contains minerals useful in the human body in the form of gluconate, it promotes the proliferation of bifidobacteria, which are beneficial bacteria in the intestines, , And the incidence of vascular diseases such as hypertension may be lowered.
Description
본 발명은 기능성 소금의 제조방법에 관한 것이다. 좀 더 구체적으로, 각종 유용 미네랄을 글루콘산염의 형태로 함유하는 기능성 소금의 제조방법 및 전기 방법으로 제조된 기능성 소금에 관한 것이다.The present invention relates to a method for producing a functional salt. More particularly, the present invention relates to a method for producing a functional salt containing various useful minerals in the form of gluconate salt, and a functional salt prepared by an electric method.
염화나트륨이 주성분인 소금은 부패방지, 발효조절 및 탈수작용 등의 성질을 이용한 식용 이외에도, 공업용과 의약용으로 광범위하게 사용되고 있으며, 식생활에서 가장 중요한 조미료인 동시에, 체액의 삼투압을 조절해 주고 인체에 필요한 여러 가지 미네랄들의 주요한 공급원의 하나로서 작용을 한다. 그러나, 근자에 들어 해양오염의 증대에 의한 유해한 금속들의 유입에 대한 우려 때문에, 정제염이나 재제염이 식탁염으로 선호되게 되었다.Salt, which is the main component of sodium chloride, is widely used for industrial and medicinal purposes as well as for edible use such as anti-corruption, fermentation control and dehydration. It is the most important seasoning in the diet and controls the osmotic pressure of body fluids It acts as one of the major sources of various minerals. However, due to concerns about the introduction of harmful metals due to increased marine pollution in the recent years, refined salt and / or remedies have become preferred as table salt.
그러나, 정제염이나 재제염은 거의 순수한 상태의 NaCl만을 함유하기 때문에 소금속에 함유된 다량의 유용한 미네랄의 공급효과가 없고, Na성분이나 Cl성분의 과다 섭취에 의한 혈압상승 유발작용에 의해 고혈압의 유발요인 중의 하나로서 작용하는 것으로 보고되어 있다. 아울러, 미네랄의 불균형을 초래하여 암의 발생률을 증가시키고, 그밖에 고혈압, 뇌일혈, 뇌경색, 당뇨병, 신장염, 심근경색증, 동맥경화증 등 각종 성인병 등을 유발하는 것으로 알려져 있다. 이러한 문제점을 극복하기 위하여, 여러 가지 미네랄 등의 유효성분이 함유된 각종 기능성 소금이 개발되어 시판되고 있으나, 이들에 함유된 유효성분은 체내에서 제대로 흡수되지 못하는 실정이다.However, since the purified or remediated salt contains only NaCl in a pure state, there is no effect of supplying a large amount of useful minerals contained in the salt, and the increase in the blood pressure due to excessive intake of the Na component and the Cl component causes the hypertension It has been reported to act as one. In addition, it is known to cause an imbalance of minerals to increase the incidence of cancer and induce various adult diseases such as hypertension, cerebral infarction, cerebral infarction, diabetes, nephritis, myocardial infarction, arteriosclerosis and the like. In order to overcome these problems, various functional salts containing various active ingredients such as minerals have been developed and marketed, but the active ingredients contained therein are not properly absorbed in the body.
따라서, 인체에 유용한 미네랄성분을 체내에서 흡수가 용이한 형태로 함유하는 기능성 소금을 개발하여야 할 필요성이 끊임없이 대두되었다.Therefore, there has been a constant need to develop a functional salt containing a mineral component useful for the human body in a form that is readily absorbable in the body.
이에, 본 발명자들은 인체에 유용한 미네랄성분을 체내에서 흡수가 용이한 형태로 함유하는 기능성 소금을 개발하고자 예의 연구 노력한 결과, 소금을 용해한 용액에 인체에 유용한 미네랄 성분들 및 글루콘산 나트륨을 첨가하고, 농축 및 재결정시켜서, 각종 미네랄 성분들을 체내에서 흡수가 용이한 글루콘산염의 형태로 함유하는 기능성 소금을 제조하여, 미네랄 성분들을 단순히 혼합한 종래의 기능성 소금들 보다 본 발명의 기능성 소금이 체내에 효과적으로 흡수됨을 확인하고, 본 발명을 완성하게 되었다.Accordingly, the present inventors have made extensive efforts to develop a functional salt containing a mineral component useful in the human body in a form that is readily absorbable in the body. As a result, it has been found that, when minerals and sodium gluconate useful in the body are added to a solution in which salt is dissolved, Concentrated and recrystallized to produce a functional salt containing various mineral components in the form of gluconate which is easy to be absorbed in the body and the functional salt of the present invention is more effective than the conventional functional salt in which mineral components are simply mixed And the present invention was completed.
결국, 본 발명의 주된 목적은 미네랄-글루콘산염을 함유하는 기능성 소금의 제조방법을 제공하는 것이다.Finally, a main object of the present invention is to provide a method for producing a functional salt containing a mineral-gluconic acid salt.
본 발명의 다른 목적은 전기 방법으로 제조된 미네랄-글루콘산염을 함유하는 기능성 소금을 제공하는 것이다.Another object of the present invention is to provide a functional salt containing a mineral-gluconate salt produced by an electrolytic method.
본 발명의 미네랄-글루콘산염을 함유하는 기능성 소금의 제조방법은 50 내지 90%(w/w)의 원료소금, 5 내지 25%(w/w)의 글루콘산 나트륨, 2 내지 12.5%(w/w)의 염화칼륨, 2 내지 12.5%(w/w)의 염화칼슘, 0.1 내지 2%(w/w)의 염화 마그네슘, 0.1 내지 2%(w/w)의 황산 아연 및 0.1 내지 1%(w/w)의 황산망간으로 구성된 원료물을 20 내지 30%(w/v)의 농도로 60 내지 80℃의 온도범위에서 가열하며 물에 용해시키는 공정; 전기 용액에 0.02 내지 0.05%(w/v)의 활성탄을 가하고 교반한 후, 여과하는 공정; 전기 여과액을 600 내지 700mmHg 감압조건하에서 가열농축하여 재결정핵을 생성한 후, 냉각시키고 재결정시키는 공정; 및, 결정을 탈수시키고, 수분함량이 0.5%(w/w) 이하가 되도록 건조하는 공정을 포함한다.The method for producing a functional salt containing a mineral-gluconate salt of the present invention comprises 50 to 90% (w / w) of a raw salt, 5 to 25% (w / w) of sodium gluconate, 2 to 12.5% (w / w) of potassium chloride, 2 to 12.5% (w / w) of calcium chloride, 0.1 to 2% (w / w) of magnesium chloride, 0.1 to 2% (w / / w) manganese sulfate at a concentration of 20 to 30% (w / v) in a temperature range of 60 to 80 占 폚 and dissolving in water; 0.02 to 0.05% (w / v) of activated carbon is added to the electric solution, stirred and filtered; Heating and concentrating the electrofiltration liquid under a reduced pressure of 600 to 700 mmHg to produce recrystallized nuclei, followed by cooling and recrystallization; And a step of dehydrating the crystals and drying so that the moisture content is 0.5% (w / w) or less.
이하, 본 발명의 미네랄-글루콘산염을 함유하는 기능성 소금의 제조방법을 공정별로 나누어 구체적으로 설명하기로 한다.Hereinafter, the method for producing a functional salt containing a mineral-gluconic acid salt of the present invention will be described in detail by dividing it into steps.
제 1공정: 원액의 수득 Step 1 : Acquisition of stock solution
50 내지 90%(w/w)의 원료소금, 5 내지 25%(w/w)의 글루콘산 나트륨, 2 내지12.5%(w/w)의 염화칼륨, 2 내지 12.5%(w/w)의 염화칼슘, 0.1 내지 2%(w/w)의 염화 마그네슘, 0.1 내지 2%(w/w)의 황산 아연 및 0.1 내지 1%(w/w)의 황산망간으로 구성된 원료물을 20 내지 30%(w/v)의 농도로 60 내지 80℃의 온도범위에서 가열하며 물에 용해시킨다: 이때, 원료소금으로는 천일염, 재제염, 정제염 등의 시판되는 소금을 모두 사용할 수 있으며, 구리, 철분 등을 추가적으로 소량 첨가할 수도 있다.(W / w) of sodium chloride, 2 to 12.5% (w / w) of potassium chloride, 2 to 12.5% (w / w) of calcium chloride By weight of a raw material consisting of 0.1 to 2% (w / w) of magnesium chloride, 0.1 to 2% (w / w) of zinc sulfate and 0.1 to 1% (w / / v) in a temperature range of 60 to 80 캜 and dissolving in water. At this time, commercially available salts such as sun salt, recrystallization salt and refined salt can be used as the raw salt, and copper May be added.
제 2공정: 여과액의 수득 Step 2 : Obtaining a filtrate
전기 용액에 0.02 내지 0.05%(w/v)의 활성탄을 가하고 교반한 후, 여과한다: 이때, 활성탄은 원액을 탈색시키고, 불순물을 제거하기 위하여 사용되며, 여과는 가압 여과기 및 여과판을 이용하여 수행함이 바람직하다.Activated carbon is added to the electric solution in an amount of 0.02 to 0.05% (w / v) of activated carbon, stirred, and filtered. At this time, the activated carbon is used for decolorizing the undiluted solution and removing impurities. Filtration is performed using a pressure filter and a filter plate .
제 3공정: 재결정 Step 3 : Recrystallization
전기 여과액을 600 내지 700mmHg 감압조건하에서 가열농축하여 재결정핵을 생성한 후, 냉각시키고 재결정시킨다: 이때, 농축은 여과액의 30 내지 50%(v/v)가 될때까지 수행함이 바람직하고, 냉각방법은 특별히 이에 제한되는 것은 아니나, 수냉식 냉각기를 사용하여 상온에서 서서히 냉각시킴이 바람직하다.The reaction solution is heated and concentrated under a reduced pressure of 600 to 700 mmHg to produce recrystallized nuclei, followed by cooling and recrystallization. The concentration is preferably 30 to 50% (v / v) of the filtrate, The method is not particularly limited thereto, but it is preferable to cool slowly at room temperature using a water-cooled cooler.
제 4공정: 결정의 탈수 및 건조 Step 4 : Dehydration and drying of crystals
결정을 탈수시키고, 수분함량이 0.5%(w/w) 이하가 되도록 건조하여, 최종적인 미네랄-글루콘산염을 함유하는 기능성 소금을 제조한다: 이때, 탈수방법은 특별히 이에 제한되는 것은 아니나, 원심분리방법을 사용함이 바람직하다.The crystals are dehydrated and dried to a water content of 0.5% (w / w) or less to prepare a functional salt containing the final mineral-gluconate salt. The dehydration method includes, but is not limited to, centrifugation It is preferable to use the separation method.
본 발명의 미네랄-글루콘산염을 함유하는 기능성 소금은 인체에 유용한 미네랄 성분들을 글루콘산염의 형태로 함유하고 있으므로, 체내에 섭취되었을 때 장내 유익균인 비피더스균의 증식을 활성화시켜서 향상된 정장효과를 나타내며, 고혈압 등의 혈관계 질환의 발병율을 낮출 수 있다.The functional salt containing the mineral-gluconate salt of the present invention contains minerals useful in the human body in the form of gluconate salt. Therefore, when the salt is ingested into the body, it activates the proliferation of bifidobacteria, which are beneficial bacteria in the intestines, , Hypertension and other vascular diseases can be reduced.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .
실시예 1: 천일염을 이용한 글루콘산염을 함유하는 기능성 소금의 제조 Example 1 Preparation of Functional Salt Containing Gluconate Salt Using Salt Salt
천일염 425g, 글루콘산 나트륨 50g, 염화 칼륨 10g, 염화 칼슘 10g 및 염화 마그네슘 5g을 70℃의 물에 용해시켜서 원액 2L를 수득하고, 활성탄 0.7g을 가하여1시간동안 상온에서 교반한 후, 여과판을 이용하여 여과하였다. 이어, 650mmHg의 감압조건에서 증발농축장치로 600ml의 부피로 농축한 다음, 수냉식 냉각기를 사용하여 상온에서 30℃ 정도까지 냉각하여 재결정하였다. 재결정된 결정을 탈수, 건조하여 글루콘산염을 함유하는 기능성 소금 365g을 제조하였으며, 이때 제조수율은 75%(w/w)임을 알 수 있었다.425 g of sodium chloride, 50 g of sodium gluconate, 10 g of potassium chloride, 10 g of calcium chloride and 5 g of magnesium chloride were dissolved in water at 70 DEG C to obtain 2 L of the undiluted solution. 0.7 g of activated carbon was added and stirred at room temperature for 1 hour, And filtered. Subsequently, the reaction mixture was concentrated to a volume of 600 ml using an evaporation concentrator under a reduced pressure of 650 mmHg, and then cooled to about 30 ° C at room temperature using a water-cooling condenser. The recrystallized crystals were dehydrated and dried to give 365 g of a functional salt containing gluconate salt. The yield was 75% (w / w).
전기 제조된 미네랄-글루콘산염을 함유하는 기능성 소금의 성분을 분석한 결과, 염화 나트륨(NaCl) 89.7%(w/w), 칼륨(K) 1.04%(w/w), 칼슘(Ca) 0.52%(w/w), 마그네슘(Mg) 0.42%(w/w) 및 글루콘산(gluconate) 5.32%(w/w)임을 알 수 있었다. 또한, 재제염인 꽃소금을 표준물질로 하여 염도를 비교한 결과, 제조된 기능성 소금은 표준물질(꽃소금)의 90% 정도의 염도를 가짐을 알 수 있었다.(NaCl), 1.04% (w / w) of potassium (K), 0.52% (w / w) of calcium (Ca) (w / w), magnesium (Mg) 0.42% (w / w) and gluconic acid 5.32% (w / w) Also, as a result of comparing the salinity of the standard salt with the recycled salt, it was found that the prepared functional salt had a salinity of about 90% of that of the standard salt.
실시예 2: 정제염을 이용한 글루콘산염을 함유하는 기능성 소금의 제조 Example 2 : Preparation of functional salt containing gluconate using purified salt
정제염 10,500g, 글루콘산 나트륨 1,300g, 염화 칼륨 675g, 염화 칼슘 524g, 황산 아연 65g 및 황산 망간 65g을 70℃의 물에 용해시켜서 원액 70L를 수득하고, 활성탄 250g을 가하여 1시간동안 상온에서 교반한 후, 여과판을 이용하여 여과하였다. 이어, 650mmHg의 감압조건에서 증발농축장치로 23L의 부피로 농축한 다음, 수냉식 냉각기를 사용하여 40℃ 정도까지 냉각하여 재결정하였다. 재결정된 결정을 탈수, 건조하여 글루콘산염을 함유하는 기능성 소금 8.2kg을 제조하였으며, 이때 제조수율은 61.7%(w/w)임을 알 수 있었다.7,550 g of purified sodium chloride, 1,300 g of sodium gluconate, 675 g of potassium chloride, 524 g of calcium chloride, 65 g of zinc sulfate and 65 g of manganese sulfate were dissolved in water at 70 DEG C to obtain 70 L of a stock solution, and 250 g of activated carbon was added thereto. After that, filtration was performed using a filter plate. Subsequently, the reaction mixture was concentrated to a volume of 23 L using an evaporation concentrator under a reduced pressure of 650 mmHg, and then cooled to about 40 캜 using a water-cooled condenser and recrystallized. The recrystallized crystals were dehydrated and dried to obtain 8.2 kg of a functional salt containing gluconate salt, and the yield was 61.7% (w / w).
전기 제조된 미네랄-글루콘산염을 함유하는 기능성 소금의 성분을 분석한 결과, 염화 나트륨(NaCl) 88.2%(w/w), 칼륨(K) 2.7%(w/w), 칼슘(Ca) 0.4%(w/w), 망간(Mn) 0.05%(w/w), 아연(Zn) 0.06%(w/w) 및 글루콘산(gluconate) 7.8%(w/w)임을 알 수 있었다.As a result of analyzing the components of the functional salt containing the minerals-gluconate produced by the electrophoresis, 88.2% (w / w) of sodium chloride (NaCl), 2.7% (w / w) of potassium (K) (w / w), manganese (Mn) 0.05% (w / w), zinc (Zn) 0.06% (w / w) and gluconate 7.8% (w / w).
실시예 3: 각종 소금에 의한 고혈압 발병률의 비교 Example 3 : Comparison of incidence of hypertension by various kinds of salt
ICR 마우스에 시판되는 정제염, 미네랄이 혼합된 정제염 및 본 발명에 의해 제조된 미네랄-글루콘산염을 함유하는 기능성 소금을 과량섭취시키고, 이로 인한 고혈압의 발병률을 측정하였다.An ICR mouse was overdosed with a commercially available tablet salt, a purified salt mixed with minerals, and a functional salt containing a mineral-gluconate salt prepared according to the present invention, and the resulting incidence of hypertension was measured.
먼저, 생후 10일된 ICR 마우스 300마리를 100마리씩 3개의 실험군으로 분류하였다. 실험군 1은 정제염을 20%(w/w)로 함유한 사료를 섭취시키고, 실험군 2는 정제염 1,050g, 글루콘산 나트륨 130g, 염화 칼륨 67.5g, 염화 칼슘 52.4g, 황산 아연 6.5g 및 황산 망간 6.5g을 혼합하고 분말화한 후, 이를 20%(w/w)로 함유한 사료를 제조하여, 이를 섭취시켰으며, 실험군 3은 전기 실시예 2에서 제조한 글루콘산염을 함유하는 기능성 소금을 20%(w/w)로 함유한 사료을 섭취시켰다. 전기 3개의 실험군을 200일 동안 사육한 후, 각 실험군에서 사망률을 측정하고, 혈관계 이상에 의한 사망률을 측정하였다(참조: 표 1).First, 300 ICR mice, 10 days old, were divided into three experimental groups of 100 mice. Experimental group 1 was fed with feed containing 20% (w / w) of purified water. Experimental group 2 contained 1,050 g of purified salt, 130 g of sodium gluconate, 67.5 g of potassium chloride, 52.4 g of calcium chloride, 6.5 g of zinc sulfate, g were mixed and powdered, and then a feed containing 20% (w / w) was prepared and taken in the experimental group 3, and the functional salt containing the gluconate prepared in Example 2 was dissolved in 20 % (w / w). Three experimental groups were raised for 200 days, and the mortality was measured in each experimental group and mortality due to vascular system abnormality was measured (see Table 1).
상기 표 1에서 보듯이, 단순히 미네랄을 혼합한 소금은 순수한 정제염보다는 고혈압에 의한 사망률을 낮출 수 있었으나, 미네랄-글루콘산염을 함유하는 기능성 소금에 의한 고혈압 사망률보다는 현저히 높음을 알 수 있었다.As shown in Table 1, it can be seen that the salt mixed with minerals alone was able to lower the mortality due to hypertension rather than the pure salt, but was significantly higher than the hypertensive mortality due to the functional salt containing mineral-gluconate.
실시예 4: 각종 소금에 의한 정장작용의 비교 Example 4 : Comparison of dressing action by various kinds of salt
전기 실시예 3과 동일한 실험군을 50일 동안 사육하고, 3일간 먹이공급을 중단한 후, 이들을 도살하여 소장 및 대장에 잔류하는 숙변의 평균무게를 비교하였다(참조: 표 2).The same experimental groups as in Example 3 were bred for 50 days, and after stopping feeding for 3 days, they were slaughtered and the average weight of the aspirates remaining in the small intestine and the large intestine were compared (see Table 2).
상기 표 2에서 보듯이, 미네랄-글루콘산염을 함유하는 기능성 소금을 섭취한실험군 3의 경우, 소장 및 대장에 잔류하는 숙변의 양이 현저히 감소됨을 알 수 있었는 바, 미네랄-글루콘산염을 함유하는 기능성 소금은 장내 유익균인 비피더스균의 증식을 활성화시켜서 향상된 정장효과를 나타냄을 알 수 있었다.As shown in Table 2, the amount of succulent residue in the small intestine and the large intestine was significantly reduced in the experimental group 3 in which the functional salt containing mineral-gluconate was consumed. As a result, The functional salt of Bifidobacterium bifidus, which is a beneficial bacterium in the intestinal tract, stimulates the proliferation of bifidobacteria.
이상에서 상세히 설명한 바와 같이, 각종 유용 미네랄을 글루콘산염의 형태로 함유하는 기능성 소금의 제조방법 및 전기 방법으로 제조된 기능성 소금을 제공한다. 본 발명의 미네랄-글루콘산염을 함유하는 기능성 소금의 제조방법은 원료소금, 글루콘산 나트륨, 염화칼륨, 염화칼슘, 염화 마그네슘, 황산 아연 및 황산망간이 용해된 원액에 활성탄을 가하고, 여과한 후, 재결정시켜서 결정을 수득한 다음, 탈수 건조하는 공정을 포함한다. 본 발명의 글루콘산염을 함유하는 기능성 소금은 인체에 유용한 미네랄 성분들을 글루콘산염의 형태로 함유하고 있으므로, 체내에 섭취되었을 때, 장내 유익균인 비피더스균의 증식을 활성화시켜서 향상된 정장효과를 나타내며, 고혈압 등의 혈관계 질환의 발병율을 낮출 수 있을 것이다.As described in detail above, the present invention provides a method for producing a functional salt containing various useful minerals in the form of gluconate salt and a functional salt prepared by an electric method. The method for producing a functional salt containing a mineral-gluconate salt of the present invention is characterized in that activated carbon is added to a raw solution in which raw material salt, sodium gluconate, potassium chloride, calcium chloride, magnesium chloride, zinc sulfate and manganese sulfate are dissolved, To obtain crystals, followed by dehydration and drying. The functional salt containing the gluconic acid salt of the present invention contains minerals useful in the human body in the form of gluconate salt. Therefore, when ingested in the body, the functional salt activates the proliferation of bifidobacteria, which are beneficial bacteria in the intestines, The incidence of vascular diseases such as hypertension may be lowered.
Claims (3)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2000-0087338A KR100383389B1 (en) | 2000-12-30 | 2000-12-30 | Process for Preparing Healthful Salt Containing Mineral Gluconate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2000-0087338A KR100383389B1 (en) | 2000-12-30 | 2000-12-30 | Process for Preparing Healthful Salt Containing Mineral Gluconate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20020057085A KR20020057085A (en) | 2002-07-11 |
| KR100383389B1 true KR100383389B1 (en) | 2003-05-12 |
Family
ID=27690194
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR10-2000-0087338A KR100383389B1 (en) | 2000-12-30 | 2000-12-30 | Process for Preparing Healthful Salt Containing Mineral Gluconate |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100383389B1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101028878B1 (en) | 2007-10-30 | 2011-04-12 | 김순동 | A preparation method of crystalline salt which has a depressive effect on blood pressure and high contents of functional minerals from sea water |
| KR101466731B1 (en) | 2014-03-27 | 2014-12-01 | (주)정진식품 | Sugar flake and method for manufacturing thereof |
| KR20170024207A (en) | 2015-08-24 | 2017-03-07 | (주)영수식품 | A method for manufacturing lite salt using dietary fiber and lite salt using dietary fiber manufactured by the same |
| KR20170024448A (en) | 2015-08-25 | 2017-03-07 | 태현식품 | Functional bay salt comprising fermentation product of crab or shrimp and manufacturing method thereof |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20020090194A (en) * | 2002-10-30 | 2002-11-30 | 도대홍 | Production of colored and flavored table salt |
| WO2004054386A1 (en) * | 2002-12-16 | 2004-07-01 | Sang-Young Park | Salt of rich minerals and production method thereof |
| KR100540908B1 (en) * | 2004-01-27 | 2006-01-11 | 하영락 | Method for producing refined salt with underground deep water |
| KR100759090B1 (en) * | 2006-02-16 | 2007-09-17 | 박상영 | The food additives enriched with the alkali and manufacturing method thereof |
| KR102390894B1 (en) | 2016-08-23 | 2022-04-25 | 정명자 | Functional salt comprising red gensing and sericite and method thereof |
| CN112586719B (en) * | 2020-12-22 | 2022-07-15 | 湖北省益欣盐产业技术研究院有限公司 | Potassium-free low-sodium edible salt and preparation method and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03139258A (en) * | 1989-10-20 | 1991-06-13 | Hiroyuki Akai | Salty seasoning |
| KR950002619A (en) * | 1993-07-07 | 1995-02-16 | 조인현 | Edible egg salt synthesized with a large amount of active mineral |
| KR970009073A (en) * | 1995-07-10 | 1997-02-24 | 이기주 | Receiver Cable Hider of Wireline Phone |
| KR20010000706A (en) * | 2000-10-06 | 2001-01-05 | 조건식 | Development of a production method and utilization of a new bioactive salt |
| JP2002029735A (en) * | 2000-07-14 | 2002-01-29 | Surugawan Kaiyo Shinsosui Kk | Method for manufacturing mineral salt |
-
2000
- 2000-12-30 KR KR10-2000-0087338A patent/KR100383389B1/en active IP Right Grant
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH03139258A (en) * | 1989-10-20 | 1991-06-13 | Hiroyuki Akai | Salty seasoning |
| KR950002619A (en) * | 1993-07-07 | 1995-02-16 | 조인현 | Edible egg salt synthesized with a large amount of active mineral |
| KR970009073A (en) * | 1995-07-10 | 1997-02-24 | 이기주 | Receiver Cable Hider of Wireline Phone |
| JP2002029735A (en) * | 2000-07-14 | 2002-01-29 | Surugawan Kaiyo Shinsosui Kk | Method for manufacturing mineral salt |
| KR20010000706A (en) * | 2000-10-06 | 2001-01-05 | 조건식 | Development of a production method and utilization of a new bioactive salt |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101028878B1 (en) | 2007-10-30 | 2011-04-12 | 김순동 | A preparation method of crystalline salt which has a depressive effect on blood pressure and high contents of functional minerals from sea water |
| KR101466731B1 (en) | 2014-03-27 | 2014-12-01 | (주)정진식품 | Sugar flake and method for manufacturing thereof |
| KR20170024207A (en) | 2015-08-24 | 2017-03-07 | (주)영수식품 | A method for manufacturing lite salt using dietary fiber and lite salt using dietary fiber manufactured by the same |
| KR20170024448A (en) | 2015-08-25 | 2017-03-07 | 태현식품 | Functional bay salt comprising fermentation product of crab or shrimp and manufacturing method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20020057085A (en) | 2002-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104473120B (en) | A kind of production technology of monosodium glutamate | |
| KR100383389B1 (en) | Process for Preparing Healthful Salt Containing Mineral Gluconate | |
| JPH07501830A (en) | Method for administering pyruvate ion and method for synthesizing pyruvate ion precursor | |
| CN108866134B (en) | Preparation method of silkworm pupa protein polypeptide chelated calcium | |
| WO2019041786A1 (en) | Salt and preparation method and system therefor | |
| CN102775340A (en) | Method for synthesizing pyroglutamic calcium glutamate with shells serving as calcium sources | |
| JP3862295B2 (en) | Anti-obesity agent | |
| US4670269A (en) | Cobalt complexes and their use as nutritional supplements | |
| US4610814A (en) | Process for the preparation of protein concentrates and nutriments by processing animal blood | |
| DE1470052A1 (en) | 3-aminopyrazinamido-guanidines and process for their preparation | |
| US2522854A (en) | 5, 6-dimethylbenzimidazole and acid salts thereof | |
| GB2210243A (en) | A magnesium additive for nutrients, feed, and medicaments | |
| CN1995010B (en) | Method for synthesizing propionyl levo-carnitine hydrochlorate | |
| CN108484630B (en) | A kind of salinomycin method of purification | |
| AU601150B2 (en) | Mineral salt composition | |
| KR100394034B1 (en) | Compositions containing easily absorbable calcium and methods for preparing the same | |
| CN111960972A (en) | Preparation process and application of taurine magnesium salt and taurine magnesium complex | |
| JPH08291190A (en) | New process for producing picolinic acid/chromium conjugate | |
| JP2596509B2 (en) | Novel glucuronic acid-containing oligosaccharide, production method thereof and use thereof | |
| CN113105352A (en) | Method for preparing food-grade and feed-grade zinc glycinate and implementation device thereof | |
| CN1065236C (en) | Synthesis of hydrochloride of betaine | |
| CN113121375A (en) | Method for preparing food-grade and feed-grade magnesium glycinate and implementation device thereof | |
| JPH08103246A (en) | Production of sea urchin-derived calcium and composition containing readily absorbable calcium obtained by the production method | |
| JPH0212467B2 (en) | ||
| WO2019013498A1 (en) | Methionine-metal chelate and production method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20130425 Year of fee payment: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20140423 Year of fee payment: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20150423 Year of fee payment: 13 |
|
| FPAY | Annual fee payment |
Payment date: 20160422 Year of fee payment: 14 |
|
| FPAY | Annual fee payment |
Payment date: 20170425 Year of fee payment: 15 |
|
| FPAY | Annual fee payment |
Payment date: 20180425 Year of fee payment: 16 |
|
| FPAY | Annual fee payment |
Payment date: 20190423 Year of fee payment: 17 |